Mitochondria are dynamic organelles whose functions are tightly regulated at multiple levels to maintain proper cellular homeostasis. Mitochondrial Sirtuin 3 (SIRT3), which belongs to an evolutionary conserved family of NAD+-dependent deacetylases, is a key regulator of the mitochondrial respiratory chain, ATP production, and fatty acid β-oxidation, and it exerts an antioxidant activity. Changes in SIRT3 expression are critical in the pathophysiology of several diseases, such as metabolic syndrome, diabetes, cancer, and aging. In experimental acute kidney injury (AKI), impairment of renal function and development of tubular injury are associated with SIRT3 reduction and mitochondrial dysfunction in proximal tubuli. SIRT3-deficient mice are more susceptible to AKI and die. Pharmacological manipulations able to increase SIRT3 preserve mitochondrial integrity, markedly limit renal injury, and accelerate functional recovery. This review highlights all the selective rescue mechanisms that point to the key role of SIRT3 as a new therapeutic target for curing renal diseases.

Keywords:
Sirtuin 3, Mitochondria, Renal diseases
1.
Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z: Regulated cell death in AKI. J Am Soc Nephrol 2014;25:2689-2701.
2.
Ernster L, Schatz G: Mitochondria: a historical review. J Cell Biol 1981;91:227S-255S.
3.
Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J: Sirtuins: the ‘magnificent seven', function, metabolism and longevity. Ann Med 2007;39:335-345.
4.
Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, Finkel T: A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A 2008;105:14447-14452.
5.
Finley LW, Haas W, Desquiret-Dumas V, Wallace DC, Procaccio V, Gygi SP, Haigis MC: Succinate dehydrogenase is a direct target of Sirtuin 3 deacetylase activity. PLoS One 2011;6:e23295.
6.
Rahman M, Nirala NK, Singh A, Zhu LJ, Taguchi K, Bamba T, Fukusaki E, Shaw LM, Lambright DG, Acharya JK, Acharya UR: Drosophila Sirt2/mammalian SIRT3 deacetylates ATP synthase beta and regulates complex V activity. J Cell Biol 2014;206:289-305.
7.
Koehler CM: Protein translocation pathways of the mitochondrion. FEBS Lett 2000;476:27-31.
8.
Guarente L: The many faces of sirtuins: sirtuins and the Warburg effect. Nat Med 2014;20:24-25.
9.
Pham-Huy LA, He H, Pham-Huy C: Free radicals, antioxidants in disease and health. Int J Biomed Sci 2008;4:89-96.
10.
Bell EL, Guarente L: The SirT3 divining rod points to oxidative stress. Mol Cell 2011;42:561-568.
11.
Galluzzi L, Kepp O, Kroemer G: Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012;13:780-788.
12.
Kinnally KW, Peixoto PM, Ryu SY, Dejean LM: Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim Biophys Acta 2011;1813:616-622.
13.
Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, Sinclair DA: Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY) 2010;2:914-923.
14.
Hoppins S, Lackner L, Nunnari J: The machines that divide and fuse mitochondria. Annu Rev Biochem 2007;76:751-780.
15.
Otera H, Wang C, Cleland MM, Setoguchi K, Yokota S, Youle RJ, Mihara K: Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. J Cell Biol 2010;191:1141-1158.
16.
Youle RJ, Narendra DP: Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011;12:9-14.
17.
Samant SA, Zhang HJ, Hong Z, Pillai VB, Sundaresan NR, Wolfgeher D, Archer SL, Chan DC, Gupta MP: SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. Mol Cell Biol 2014;34:807-819.
18.
Hebert AS, Dittenhafer-Reed KE, Yu W, Bailey DJ, Selen ES, Boersma MD, Carson JJ, Tonelli M, Balloon AJ, Higbee AJ, Westphall MS, Pagliarini DJ, Prolla TA, Assadi-Porter F, Roy S, Denu JM, Coon JJ: Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell 2013;49:186-199.
19.
Bellizzi D, Rose G, Cavalcante P, Covello G, Dato S, De Rango F, Greco V, Maggiolini M, Feraco E, Mari V, Franceschi C, Passarino G, De Benedictis G: A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 2005;85:258-263.
20.
Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G: Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009;119:524-530.
21.
Macconi D, Perico L, Longaretti L, Morigi M, Cassis P, Buelli S, Perico N, Remuzzi G, Benigni A: Sirtuin3 dysfunction is the key determinant of skeletal muscle insulin resistance by angiotensin II. PLoS One 2015;10:e0127172.
22.
Sundaresan NR, Bindu S, Pillai VB, Samant S, Pan Y, Huang JY, Gupta M, Nagalingam RS, Wolfgeher D, Verdin E, Gupta MP: SIRT3 blocks aging-associated tissue fibrosis in mice by deacetylating and activating GSK3beta. Mol Cell Biol 2015;pii:MCB.00586-15.
23.
Morigi M, Perico L, Rota C, Longaretti L, Conti S, Rottoli D, Novelli R, Remuzzi G, Benigni A: Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J Clin Invest 2015;125:715-726.
24.
Mehta RL, Cerdá J, Burdmann EA, Tonelli M, García-García G, Jha V, Susantitaphong P, Rocco M, Vanholder R, Sever MS, Cruz D, Jaber B, Lameire NH, Lombardi R, Lewington A, Feehally J, Finkelstein F, Levin N, Pannu N, Thomas B, Aronoff-Spencer E, Remuzzi G: International society of nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 2015;385:2616-2643.
25.
Koyama T, Kume S, Koya D, Araki S, Isshiki K, Chin-Kanasaki M, Sugimoto T, Haneda M, Sugaya T, Kashiwagi A, Maegawa H, Uzu T: SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. Free Radic Biol Med 2011;51:1258-1267.
26.
Zhuo L, Fu B, Bai X, Zhang B, Wu L, Cui J, Cui S, Wei R, Chen X, Cai G: NAD blocks high glucose induced mesangial hypertrophy via activation of the sirtuins-AMPK-mTOR pathway. Cell Physiol Biochem 2011;27:681-690.
27.
Pillai VB, Sundaresan NR, Jeevanandam V, Gupta MP: Mitochondrial SIRT3 and heart disease. Cardiovasc Res 2010;88:250-256.
28.
Duan W: Sirtuins: from metabolic regulation to brain aging. Front Aging Neurosci 2013;5:36.
29.
Weir HJ, Lane JD, Balthasar N: SIRT3: a central regulator of mitochondrial adaptation in health and disease. Genes Cancer 2013;4:118-124.
30.
Chen Y, Fu LL, Wen X, Wang XY, Liu J, Cheng Y, Huang J: Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis 2014;5:e1047.
31.
Jasper H: Sirtuins: longevity focuses on NAD+. Nat Chem Biol 2013;9:666-667.
32.
Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, Arbiser JL, Walker DI, Jones DP, Gius D, Gupta MP: Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun 2015;6:6656.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.